Want to see IN:GUFICBIO full AI Analyst Report?
Top Page
Gufic Biosciences Limited
(GUFICBIO)
Select Model
Select Model
Rating:58Neutral
Price Target:
₹456.00
▲(20.56% Upside)
Action:Reiterated
Date:09/30/26
The score is held back primarily by weak and volatile cash flows (sharp FY2026 operating cash flow decline and negative free cash flow) and a high P/E valuation. Offsetting these risks, the technical setup is positive with the stock trading above major moving averages and moderate momentum readings.
Positive Factors
Pharmaceutical portfolio and market reach
A diversified formulation portfolio across therapeutic areas, including injectable products, gives Gufic multiple avenues to serve domestic and international demand. Manufacturing and marketing capabilities can support recurring product sales and broaden opportunities beyond any single medicine or market.
Negative Factors
Weak and volatile cash generation
The sharp deterioration in operating cash flow and negative free cash flow show that reported earnings are not converting reliably into cash. Persistent volatility can constrain reinvestment, increase reliance on financing, and reduce resilience when working-capital or investment needs rise.
Read all positive and negative factors
Positive Factors
Negative Factors
Pharmaceutical portfolio and market reach
A diversified formulation portfolio across therapeutic areas, including injectable products, gives Gufic multiple avenues to serve domestic and international demand. Manufacturing and marketing capabilities can support recurring product sales and broaden opportunities beyond any single medicine or market.
Read all positive factors
Gufic Biosciences Limited (GUFICBIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹43.92B
Dividend Yield0.02%
Average Volume (3M)6.53K
Price to Earnings (P/E)59.0
Beta (1Y)0.70
Revenue Growth16.70%
EPS Growth18.73%
CountryIN
Employees1,491
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)7.32
Shares Outstanding100,282,510
10 Day Avg. Volume4,536
30 Day Avg. Volume6,527
Financial Highlights & Ratios
PEG Ratio-5.32
Price to Book (P/B)4.13
Price to Sales (P/S)2.91
P/FCF Ratio-152.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Gufic Biosciences Limited Business Overview & Revenue Model
Company Description
Gufic Biosciences Limited is an Indian enterprise dedicated to the manufacturing and marketing of active pharmaceutical ingredients (APIs), generic medications, and related support services. The company's API and bulk drug offerings include antifu...
How the Company Makes Money
Gufic Biosciences makes money primarily by selling pharmaceutical products (finished dosage formulations) that it manufactures and markets. Key revenue streams typically include: (1) Domestic formulations sales: revenues from the sale of branded a...
Gufic Biosciences Limited Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
68
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.81B | 9.44B | 8.20B | 8.07B | 6.91B | 7.79B |
| Gross Profit | 4.52B | 3.40B | 2.97B | 4.07B | 3.51B | 3.56B |
| EBITDA | 1.64B | 1.54B | 1.38B | 1.48B | 1.37B | 1.48B |
| Net Income | 734.57M | 642.15M | 696.50M | 861.36M | 797.05M | 958.40M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 13.42B | 11.69B | 10.93B | 8.61B | 5.21B |
| Cash, Cash Equivalents and Short-Term Investments | 621.86M | 762.17M | 290.22M | 11.37M | 286.02M | 116.08M |
| Total Debt | 0.00 | 4.05B | 3.36B | 3.33B | 3.34B | 643.87M |
| Total Liabilities | -6.65B | 6.77B | 5.68B | 5.60B | 5.13B | 2.52B |
| Stockholders Equity | 6.65B | 6.65B | 6.01B | 5.33B | 3.48B | 2.69B |
Cash Flow | ||||||
| Free Cash Flow | 434.82M | -180.11M | 270.96M | -1.20B | -2.14B | 187.86M |
| Operating Cash Flow | 591.15M | 131.71M | 1.03B | -74.57M | -265.87M | 1.06B |
| Investing Cash Flow | -152.90M | -319.73M | -717.09M | -1.02B | -1.91B | -945.89M |
| Financing Cash Flow | 150.53M | 652.67M | -163.26M | 823.81M | 2.34B | -62.44M |
Gufic Biosciences Limited Technical Analysis
Positive
378.25
Price Trends
417.12
Positive
385.85
Positive
345.87
Positive
Market Momentum
3.35
Positive
53.25
Neutral
50.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GUFICBIO, the sentiment is Positive. The current price of 378.25 is below the 20-day moving average (MA) of 432.27, below the 50-day MA of 417.12, and above the 200-day MA of 345.87, indicating a neutral trend. The MACD of 3.35 indicates Positive momentum. The RSI at 53.25 is Neutral, neither overbought nor oversold. The STOCH value of 50.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GUFICBIO.
Gufic Biosciences Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹75.50B | 54.34 | ― | 0.21% | 20.59% | 27.16% | |
61 Neutral | ₹65.10B | 49.21 | ― | 0.16% | 9.48% | 50.50% | |
58 Neutral | ₹43.92B | 59.02 | ― | 0.02% | 16.70% | 18.73% | |
57 Neutral | ₹60.58B | 583.04 | ― | 16.67% | 10.83% | -89.82% | |
57 Neutral | ₹39.95B | 12.60 | ― | 1.34% | 9.43% | 132.94% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
47 Neutral | ₹24.83B | 902.31 | ― | 0.08% | 12.08% | ― |
* General Sector Average
IN:GUFICBIO
Gufic Biosciences Limited
431.75
79.84
22.69%
IN:BLISSGVS
Bliss Gvs Pharma Limited
695.35
542.98
356.35%
IN:INDOCO
Indoco Remedies Limited
263.10
-28.45
-9.76%
IN:MOREPENLAB
Morepen Laboratories Limited
126.00
77.28
158.63%
IN:ORCHPHARMA
Orchid Pharma Limited
995.85
251.50
33.79%
IN:UNICHEMLAB
Unichem Laboratories Limited
546.35
55.00
11.19%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.